Pharmaceutical compositions for combination therapy

1. A method for treating an inflammatory, metabolic, fibrotic or cholestatic disease modulated by transforming growth factor β (TGF-β) in a subject in need thereof, the method comprising administering to the subject:

(i) a compound selected from the group consisting of nitazoxanide (NTZ), tizoxanide, and a pharmaceutically acceptable salt thereof; and

(ii) at least one PPAR agonist selected from the group consisting of elafibranor, seladelpar, saroglitazar, lanifibranor, and a pharmaceutical salt thereof.

2. The method of claim 1 , wherein the method comprises administering to the subject:

(i) a compound selected from the group consisting of nitazoxanide, tizoxanide, and a pharmaceutical salt thereof; and

(ii) Elafibranor or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound and the at least one PPAR agonist is in a composition further comprising a pharmaceutically acceptable carrier.

4. The method of claim 1 , wherein the compound and the at least one PPAR agonist is in a kit for sequential, separate or simultaneous use.

5. The method of claim 1 , wherein the compound and the at least one PPAR agonist are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an ointment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

6. The method of claim 1 , wherein the fibrotic disease is selected from the group consisting of liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, ovary, adrenal gland, artery, vein, colon, intestine, biliary tract, soft tissue, bone marrow, joint and stomach fibrosis.

7. The method of claim 1 , wherein the inflammatory, metabolic, fibrotic or cholestatic disease is selected from the group consisting of, metabolic liver diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced liver diseases, alcohol-induced liver diseases, infectious agent induced liver diseases, inflammatory liver diseases, immune system dysfunction-mediated liver diseases, dyslipidemia, cardiovascular diseases, restenosis, syndrome X, metabolic syndrome, diabetes, obesity, hypertension, chronic cholangiopathies.

8. The method of claim 1 , wherein the fibrotic disease is selected from the group consisting of liver, gut, lung, heart, kidney, muscle, skin, soft tissue, bone marrow, intestinal, and joint fibrosis.

9. The method of claim 1 , wherein the inflammatory, metabolic, fibrotic or cholestatic disease is primary sclerosing cholangitis (PSC), or primary biliary cholangitis (PBC).